Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Current Topics in Medicinal Chemistry

• Publication date

  2010-11-30

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/156802610792927997PMID 20645912
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human Brain Imaging and Radiation Dosimetry of 11C-N-Desmethyl-Loperamide, a PET Radiotracer to Measure the Function of P-Glycoprotein

  2009cited by this paper
• Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.

  2009cited by this paper
• Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET

  2009cited by this paper
• Noninvasive and Quantitative Assessment of the Function of Multidrug Resistance-Associated Protein 1 in the Living Brain

  2009cited by this paper
• Receptor Occupancy and Brain Free Fraction

  2009cited by this paper
• Synthesis and preclinical evaluation of novel PET probes for P-glycoprotein function and expression.

  2009cited by this paper
• Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats.

  2009cited by this paper
• Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs

  2009cited by this paper
• Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport

  2009cited by this paper
• Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier.

  2009cited by this paper
• 11C-Loperamide and Its N-Desmethyl Radiometabolite Are Avid Substrates for Brain Permeability-Glycoprotein Efflux

  2008cited by this paper
• Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function.

  2008cited by this paper
• Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease.

  2008cited by this paper
• Positron emission tomography and target-controlled infusion for precise modulation of brain drug concentration.

  2008cited by this paper
• Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier.

  2008cited by this paper
• Toward an improved prediction of human in vivo brain penetration

  2008cited by this paper
• Effect of a P‐glycoprotein inhibitor, cyclosporin A, on the disposition in rodent brain and blood of the 5‐HT1A receptor radioligand, [11C](R)‐(––)‐RWAY

  2007cited by this paper
• In Vitro Methods for Estimating Unbound Drug Concentrations in the Brain Interstitial and Intracellular Fluids

  2007cited by this paper
• Inhibition of P-glycoprotein Activity at the Primate Blood-Brain Barrier Increases the Distribution of Nelfinavir into the Brain but Not into the Cerebrospinal Fluid

  2007cited by this paper
• On The Rate and Extent of Drug Delivery to the Brain

  2007cited by this paper
• Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands

  2007cited by this paper
• Evaluation of Tracer Kinetic Models for Quantification of P-Glycoprotein Function using (R)-[11C]Verapamil and PET

  2007cited by this paper
• Quantification of serotonin 5‐HT1A receptors in humans with [11C](R)‐(−)‐RWAY: Radiometabolite(s) likely confound brain measurements

  2007cited by this paper
• Pharmacoresistance in Epilepsy: A Pilot PET Study with the P‐Glycoprotein Substrate R‐[11C]verapamil

  2007cited by this paper
• Quantification of serotonin 5‐HT1A receptors in monkey brain with [11C](R)‐(−)‐RWAY

  2006cited by this paper
• Verapamil P-glycoprotein Transport across the Rat Blood-Brain Barrier: Cyclosporine, a Concentration Inhibition Analysis, and Comparison with Human Data

  2006cited by this paper
• In Vivo Evaluation of P-glycoprotein Function at the Blood-Brain Barrier in Nonhuman Primates Using [11C]Verapamil

  2006cited by this paper
• BRAIN DISTRIBUTION OF CETIRIZINE ENANTIOMERS: COMPARISON OF THREE DIFFERENT TISSUE-TO-PLASMA PARTITION COEFFICIENTS: Kp, Kp,u, AND Kp,uu

  2006cited by this paper
• Pharmacokinetic Consequences of Active Drug Efflux at the Blood–Brain Barrier

  2006cited by this paper
• Effect of age on functional P‐glycoprotein in the blood‐brain barrier measured by use of (R)‐[11C]verapamil and positron emission tomography

  2006cited by this paper
• Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET

  2006cited by this paper
• Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography

  2005cited by this paper
• Blood–brain barrier dysfunction in parkinsonian midbrain in vivo

  2005cited by this paper
• New positron emission tomography tracer [11C]carvedilol reveals P‐glycoprotein modulation kinetics

  2005cited by this paper
• Synthesis and evaluation of dopamine D3 receptor antagonist 11C-GR218231 as PET tracer for P-glycoprotein.

  2005cited by this paper
• Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat.

  2005cited by this paper
• Steady-State Brain Concentrations of Antihistamines in Rats

  2004cited by this paper
• P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists.

  2003cited by this paper
• Comment regarding Bergmann et al.'s "Assessment of the in vitro and in vivo properties of a 99mTc-labeled inhibitor of the multidrug resistant gene product of P-glycoprotein".

  2003cited by this paper
• Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET

  2003cited by this paper
• Role of multidrug transporters in pharmacoresistance to antiepileptic drugs.

  2002cited by this paper
• Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery

  2002cited by this paper
• Investigation of the high partition of YM992, a novel antidepressant, in rat brain ‐ in vitro and in vivo evidence for the high binding in brain and the high permeability at the BBB

  2002cited by this paper
• Positron Emission Tomography Compartmental Models

  2001cited by this paper
• Enhanced cerebral uptake of receptor ligands by modulation of P‐glycoprotein function in the blood–brain barrier

  2000cited by this paper
• Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.

  2000cited by this paper
• Influence of P-glycoprotein on brain uptake of [18F]MPPF in rats.

  2000cited by this paper
• Modelling of the blood‐brain barrier transport of morphine‐3‐glucuronide studied using microdialysis in the rat: involvement of probenecid‐sensitive transport

  2000cited by this paper
• Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.

  2000cited by this paper
• A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.

  1999cited by this paper
• The Simultaneous Estimation of the Influx and Efflux Blood-Brain Barrier Permeabilities of Gabapentin Using a Microdialysis-Pharmacokinetic Approach

  1996cited by this paper
• Cerebral blood flow, blood volume, and brain tissue hematocrit during isovolemic hemodilution with hetastarch in rats.

  1992cited by this paper
• Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier.

  1990cited by this paper
• Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects

  1990cited by this paper
• Estimates of Michaelis-Menten Constants for the Two Membranes of the Brain Endothelium

  1984cited by this paper
• Ion diffusion modified by tortuosity and volume fraction in the extracellular microenvironment of the rat cerebellum.

  1981cited by this paper

• Innovative Approaches to Optimize Clinical Transporter Drug–Drug Interaction Studies

  2024cites this paper
• Targeting Transporters for Drug Delivery to the Brain: Can We Do Better?

  2022cites this paper
• [11C]phenytoin quantification using parametric methods

  2017cites this paper
• Chapter 6 [ 11 C ] phenytoin quantification using parametric methods

  2017cites this paper
• Combined PET and microdialysis for in vivo estimation of drug blood‐brain barrier transport and brain unbound concentrations

  2017cites this paper
• Parametric Methods for Dynamic 11C-Phenytoin PET Studies

  2017cites this paper
• Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design.

  2016cites this paper
• Blood-Brain Barrier ABC-transporter P-glycoprotein in Alzheimer's Disease: Still a Suspect?

  2016cites this paper
• Mass spectrometry imaging in drug development.

  2015cites this paper
• Quantitative Aspects of Nanodelivery Across the Blood-Brain Barrier Exemplified with the Opioid Peptide

  2015cites this paper
• Quantitative Aspects of Nanodelivery Across the Blood-Brain Barrier : Exemplified with the Opioid Peptide DAMGO

  2015cites this paper
• The Role of P-Glycoprotein in Psychiatric Disorders and in Psychiatric Treatment

  2014cites this paper
• Pharmacokinetic Concepts in Brain Drug Delivery

  2014cites this paper
• Resistance to the macrocyclic lactone moxidectin is mediated in part by membrane transporter P-glycoproteins: Implications for control of drug resistant parasitic nematodes

  2014cites this paper
• Principles of PET and Its Role in Understanding Drug Delivery to the Brain

  2014cites this paper
• Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.

  2013cites this paper
• Physiologically Based Pharmacokinetic Modelling of Drug Penetration Across the Blood–Brain Barrier—Towards a Mechanistic IVIVE-Based Approach

  2013cites this paper
• 99mTc(N)-DBODC(5), a potential radiolabeled probe for SPECT of multidrug resistance: in vitro study

  2013cites this paper
• Challenges of Using In Vitro Data for Modeling P-Glycoprotein Efflux in the Blood-Brain Barrier

  2013cites this paper
• In Vitro P-glycoprotein Efflux Ratio Can Predict the In Vivo Brain Penetration Regardless of Biopharmaceutics Drug Disposition Classification System Class

  2013cites this paper
• Inhibition of P-glycoprotein enhances sensitivity of Caenorhabditis elegans to ivermectin.

  2013cites this paper
• Overview of Experimental Models of the Blood‐Brain Barrier in CNS Drug Discovery

  2013cites this paper
• [11C]quinidine and [11C]laniquidar PET imaging in a chronic rodent epilepsy model: impact of epilepsy and drug-responsiveness.

  2013cites this paper
• In vitro P-gp efflux ratio can predict the in vivo brain penetration regardless of BDDCS class

  2013cites this paper
• Impact of epilepsy and drug-responsiveness☆

  2013cites this paper
• In Vivo Approaches to Assessing the Blood–Brain Barrier

  2013cites this paper
• DMD053868 2012..2017

  2013cites this paper
• Interactions between antidepressants and P‐glycoprotein at the blood–brain barrier: clinical significance of in vitro and in vivo findings

  2012cites this paper
• Reproducibility of quantitative (R)-[11C]verapamil studies

  2012cites this paper
• [11C]phenytoin revisited: synthesis by [11C]CO carbonylation and first evaluation as a P-gp tracer in rats

  2012cites this paper
• Special Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems—Minireview In Vitro P-glycoprotein Efflux Ratio Can Predict the In Vivo Brain Penetration Regardless of Biopharmaceutics Drug Disposition Classification System Class

  2012cites this paper
• Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood–brain barriers studied with (R)-[11C]verapamil positron emission tomography

  2012cites this paper
• ORIGINAL RESEARCH Open Access Reproducibility of quantitative (R)-( 11 C)verapamil

  2012cites this paper
• Analytical and biological methods for probing the blood-brain barrier.

  2012cites this paper
• Developmental Changes in P-Glycoprotein Function in the Blood–Brain Barrier of Nonhuman Primates: PET Study with R-11C-Verapamil and 11C-Oseltamivir

  2011cites this paper
• Imaging of ABC transporter function and expression.

  2010cites this paper
• tracers for probing P-glycoprotein function: kinetics, advantages and disadvantages. Curr Top Med Chem (12) Piwnica-Worms D, and Sharma V. Probing multidrug resistance P-glycoprotein transporter activity with SPECT radiopharmaceuticals. Curr Top Med Chem

  2010cites this paper
• suMMarY, disCussiOn and future perspeCtives

  2010cites this paper